ArticleFrontiers in microbiology2021
Genetic Plurality of OXA/NDM-Encoding Features Characterized From
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Wildlife as a reservoir of OXA-48-like carbapenemase-producing Enterobacterales.Microbiology spectrum · 2026Article
- Predatory myxobacteria lay at the cross-roads of metallo-β-lactamase evolution.Communications biology · 2026Article
- Carbapenem and colistin-resistantJAC-antimicrobial resistance · 2026Article
- Antimicrobial Resistance and Comparative Genome Analysis of High-RiskMicroorganisms · 2026Article
- Article
- Dissemination of aFrontiers in microbiology · 2026Article
- Diversity in Carbapenemases in Enterobacterales in Southeastern Austria Before and During the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2025Article
- Global dissemination of conjugative virulence plasmids co-harboring hypervirulence and multidrug resistance genes inmSystems · 2025Article
- Rapidly spreadingJournal of clinical microbiology · 2025Review
- Carbapenemase-Producing Enterobacterales from Patients Arriving from Ukraine in Poland, March 2022-February 2023.Infectious diseases and therapy · 2025Article
- Circulation of a UniqueAntibiotics (Basel, Switzerland) · 2025Article
- High-Risk Lineages of Hybrid Plasmids Carrying Virulence and Carbapenemase Genes.Antibiotics (Basel, Switzerland) · 2024Article
- Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales andAntibiotics (Basel, Switzerland) · 2024Review
- Article
- Comparative genomics of an extensively drug resistant strain Klebsiella pneumoniae IITR008 with international high-risk clonal lineage ST147 isolated from river water.Antonie van Leeuwenhoek · 2024Article
- Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread ofFrontiers in cellular and infection microbiology · 2024Article
- FosA3 emerging in clinical carbapenemase-producingFrontiers in cellular and infection microbiology · 2024Article
- Molecular characterization of IncFII plasmid carryingmSphere · 2023Article
- Epidemiological Characterisation ofMicroorganisms · 2023Article
- Polyclonal Spread of Fosfomycin Resistance among Carbapenemase-Producing Members of theMicrobiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to characterize four
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.